International Society for Pediatric and Adolescent Diabetes

JDRF Encouraged by Results of PROTECT Clinical Trial

Retrieved on: 
Wednesday, October 18, 2023
International Society for Pediatric and Adolescent Diabetes, JDRF, PROTECT, Research, Disease, Clinical trial, Risk, The New England Journal of Medicine, C-peptide, Sanofi, International Society, T1D, ISPAD, Vaccine, Pharmaceutical industry

The trial investigated whether TZIELD can slow the loss of beta cells and preserve beta cell function, as measured by C-peptide, in newly diagnosed (stage 3 T1D) children and adolescents ages 8-17.

Key Points: 
  • The trial investigated whether TZIELD can slow the loss of beta cells and preserve beta cell function, as measured by C-peptide, in newly diagnosed (stage 3 T1D) children and adolescents ages 8-17.
  • The results were also published today in the New England Journal of Medicine .
  • "Preserving beta cell function in individuals diagnosed with type 1 diabetes is a critical step towards cures and, crucially, is helpful in type 1 diabetes management," said Sanjoy Dutta, Ph.D., JDRF chief scientific officer.
  • JDRF appreciates Provention Bio and Sanofi's ongoing commitment to individuals diagnosed with type 1 diabetes and applauds all efforts aimed at finding cures and improving therapies for this population."

Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting

Retrieved on: 
Friday, May 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, CXS, Hippeastrum mirum, CET, SBA, Cholesterol, Research, Publication, AdventHealth, Doctor of Philosophy, Medication, Xanthoma, Hypercholesterolemia, Professor, Patient, Fracture, Augmented fifth, Itch, Bilirubin, Annual general meeting, Bile, Gastrointestinal bleeding, International Society for Pediatric and Adolescent Diabetes, Liver, Poster, IBAT, Alagille syndrome, GI, PFIC, Cholestatic pruritus, Safety, Pharmaceutical industry, Nightclub, Dietary supplement, ALGS, Nutrition, Gastroenterology

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 55th European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 55th European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting.
  • Among the data presented were four oral and three poster presentations featuring analyses from LIVMARLI® (maralixibat) oral solution clinical studies.
  • The analysis evaluated the impact of LIVMARLI on xanthomas using data from ALGS studies.
  • The data showed that LIVMARLI was well-tolerated in a real-world setting with lower rates of adverse events than described in clinical trials.

Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting

Retrieved on: 
Wednesday, May 17, 2023
Health, Science, Pharmaceutical, Research, Clinical Trials, Abstract, CET, Safety, AdventHealth, Medication, Hypercholesterolemia, AP-HP, Professor, Patient, Annual general meeting, Bile, RISE, International Society for Pediatric and Adolescent Diabetes, Exhibition, Alagille syndrome, European Society of Neurogastroenterology and Motility, PFIC, Cholestatic pruritus, Pharmaceutical industry, Dentistry, Nightclub, Nutrition, Gastroenterology

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present data at the upcoming 55th Annual European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting, taking place May 17-20, 2023, in Vienna, Austria.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present data at the upcoming 55th Annual European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting, taking place May 17-20, 2023, in Vienna, Austria.
  • The company will present data from its LIVMARLI® (maralixibat) oral solution clinical studies in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC).
  • Data from Mirum’s studies of LIVMARLI® (maralixibat) oral solution include oral and poster presentations:
    Presented at 1:02pm CET by Professor Richard J. Thompson, King’s College, London
    Abstract 468- H-O029: Maralixibat improves cholestatic pruritus and bile acids in children with FIC1: Data from the MARCH-PFIC trial
    Friday, May 19, 2023 – 12:00-1:00pm - Parallel Session: Hepatology-Abstract Session 02, Hall G
    Presented at 12:00pm CET by Professor Richard J. Thompson, King’s College, London
    Abstract 472 – H-O010: Maralixibat improves xanthomas and hypercholesterolemia in children with Alagille syndrome: an integrated analysis from two clinical trials
    Friday, May 19, 2023 – 12:00-1:00pm - Parallel Session: Hepatology-Abstract Session 02, Hall G
    Presented at 12:32pm CET Dr. Brett Hoskins, The Johns Hopkins Hospital School of Medicine, Baltimore, Maryland
    Presented at 12:40pm CET by Dr. Regino P. Gonzalez-Peralta, AdventHealth for Children and AdventHealth Transplant Institute, Orlando, Florida
    Abstract 473: Safety and tolerability of maralixibat in infants from two months of age with Alagille syndrome or progressive familial intrahepatic cholestasis: Results from the RISE study
    Friday, May 19, 2023 – 2:40-3:30pm CET – Poster Walk Hepatology 02: General Hepatology I, Exhibition Area
    Presented at 2:56pm CET by Professor Emanuel Gonzales, Hépatologie Pédiatrique, Hôpital Bicêtre, AP-HP, Université Paris-Saclay, Le Kremlin-Bicêtre, France
    Abstract 469: Maralixibat, an ileal bile acid transporter inhibitor, delays the need for liver transplant in patients with Alagille syndrome: Real-world experience
    Friday, May 19, 2023 – 2:40-3:30pm CET –Hepatology 02: General Hepatology I, Exhibition Hall
    Friday, May 19, 2023 – 2:40-3:30pm CET –Hepatology 02: General Hepatology I, Exhibition Hall
    All abstracts will be available on the ESPGHAN website via the ESPGHAN website on May 17, 2023.

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
Tuesday, December 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
Tuesday, December 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, Multimedia, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

JDRF Announces Launch of global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Time, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, CDN, Insulin, Industry, Diabetes, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, The Lancet, International Society, Diagnosis, IDF, Heart, Research, GLOBE, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Management, Medical device, Child, Index, Facebook, Instagram, T1D, Lilly

TORONTO and NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index).

Key Points: 
  • TORONTO and NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index).
  • The T1D Index and accompanying research has been published in the world leading diabetes and endocrinology medical journal, The Lancet Diabetes & Endocrinology.
  • This is why I am so proud that significant progress has been made to understand T1Ds global impact through the T1D Index.
  • It is a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

JDRF Announces Launch of Global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, Insulin, Industry, Abbott, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, International Society, Diagnosis, IDF, Heart, Research, Awareness, Multimedia, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, View, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Medical device, Seaweed, Child, Index, Facebook, Instagram, T1D, Lilly

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.

Key Points: 
  • The first-of-its-kind index will raise awareness of the burden and unmet need of people living with type 1 diabetes around the world.
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF , the leading global type 1 diabetes (T1D) research and advocacy organization, announcesthe launch of the Type 1 Diabetes Index (T1D Index).The T1D Index is afirst-of-its-kind data simulationtool that measures the human and public health impact of the T1D crisis in every country across the globe.
  • The T1DIndex and accompanying research has been published in the leading diabetes and endocrinology medical journal, The Lancet Diabetes &Endocrinology.
  • Itis a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

JDRF Announces Launch of Global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, Insulin, Industry, Abbott, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, International Society, Diagnosis, IDF, Heart, Research, Awareness, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Medical device, Seaweed, Child, Index, Facebook, Instagram, T1D, Lilly

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.

Key Points: 
  • The first-of-its-kind index will raise awareness of the burden and unmet need of people living with type 1 diabetes around the world.
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF , the leading global type 1 diabetes (T1D) research and advocacy organization, announcesthe launch of the Type 1 Diabetes Index (T1D Index).The T1D Index is afirst-of-its-kind data simulationtool that measures the human and public health impact of the T1D crisis in every country across the globe.
  • The T1DIndex and accompanying research has been published in the leading diabetes and endocrinology medical journal, The Lancet Diabetes &Endocrinology.
  • Itis a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Retrieved on: 
Thursday, September 23, 2021
ISPAD, Clinical trial, Diamyd Medical, International Society for Pediatric and Adolescent Diabetes, Hyperglycemia, GAD65, Society, Hannelius, ASHG, Diabetes, Patient, Type 1, Glycated hemoglobin, Eli Lilly and Company, Pediatrics, Continuous glucose monitor, International Society of Sculptors, Painters and Gravers, CEO, Blood, Meta-analysis, Company, Adolescence, Congress, Uppsala University Hospital, Human genetics, CGM, Hypoglycemia, Insulin, IIB, HLA, Nasdaq, EASD, Regeneration, Pharmaceutical industry

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Retrieved on: 
Thursday, September 23, 2021
ISPAD, Clinical trial, Diamyd Medical, International Society for Pediatric and Adolescent Diabetes, Hyperglycemia, GAD65, Society, Hannelius, ASHG, Diabetes, Patient, Type 1, Glycated hemoglobin, Eli Lilly and Company, Pediatrics, Continuous glucose monitor, International Society of Sculptors, Painters and Gravers, CEO, Blood, Meta-analysis, Company, Adolescence, Congress, Uppsala University Hospital, Human genetics, CGM, Hypoglycemia, Insulin, IIB, HLA, Nasdaq, EASD, Regeneration, Pharmaceutical industry

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.